– Vir Biotechnology (VIR) to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to ...

Read full article: SUNDAY: Flooding risk high east of San Antonio, but strong storms are still possible for the Alamo City Julie Irvin Hartman started her Tuesday with welcome, but confusing news. The ...

Caused by: org.eclipse.birt.report.data.adapter.api.AdapterException: An exception occurred during processing. Please see the following message for details: Failed to ...

TIOBE Programming Index News October 2025: C Edges Past C++ as SQL Returns to the Top 10 Your email has been sent The October 2025 TIOBE Index saw a reshuffling beneath Python’s still-commanding lead.

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

(RTTNews) - Northrop Grumman Corp. (NOC), Thursday announced that it has committed $50 million to Firefly Aerospace to accelerate production of their jointly developed medium class launch vehicle, ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...